Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis
1996

Dosing Carboplatin and Etoposide in Dialysis Patients

Sample size: 2 publication Evidence: low

Author Information

Author(s): MW English, SP Lowis, B Peng, A Boddy, DR Newell, L Price, ADJ Pearson

Primary Institution: Children's Cancer Unit, Sir James Spence Institute of Child Health; Cancer Research Unit, The Medical School, The Royal Victoria Infirmary

Hypothesis

Can pharmacokinetically guided dosing of carboplatin and etoposide be effectively administered to patients undergoing dialysis?

Conclusion

Pharmacokinetic monitoring is essential for administering carboplatin and etoposide to patients with renal failure requiring dialysis.

Supporting Evidence

  • Carboplatin and etoposide were administered based on pharmacokinetic monitoring.
  • Neither drug was cleared by peritoneal dialysis, but carboplatin was cleared by haemodialysis.
  • Both patients developed significant haematological toxicity.

Takeaway

Doctors can give special cancer drugs to kids and adults on dialysis, but they need to check how much of the drug is in their blood to keep them safe.

Methodology

The study involved pharmacokinetic monitoring and adaptive control of dosing based on drug plasma concentration measurements.

Limitations

The study involved only two patients, limiting the generalizability of the findings.

Participant Demographics

One patient was a 4.3-year-old girl and the other was a 17-year-old male.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication